6th Neuroimmunology Drug Development The Colonnade, Boston

Neuroimmunology discovery has continued to expand over the past year, with emerging and continued biology and target investigation against TREM2, RIPK1, ferroptosis, NLRP3, LRRK2, and beyond. However, there are still significant translational barriers to overcome to see clinical success of neuroinflammatory modulators and tackle the huge unmet patient need in neurology.

Characterizing and harnessing functions and interactions of microglia, astrocytes, oligodendrocytes, and infiltrating adaptive immune cells are key to discovering and developing therapies to treat underlying neuroinflammation in Alzheimer’s, Parkinson’s, multiple sclerosis, and beyond.

Join 100+ biopharma experts from Alector, Lundbeck, Vigil Neuroscience, Biogen, BMS, Muna Therapeutics, Pipeline Therapeutics, PTC Therapeutics, and more, breaking down novel glial biology and neuroinflammatory target investigation, adaptive immunity contributions, state of the art microglial iPSCs, humanized rodent models, neuroinflammatory biomarkers, and early clinical learnings to optimize neuroimmunology translation and develop transformative therapeutics for neurological disorders.